Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Corticosteroids treatment.

Carlo Pozzilli1, Fabiana Marinelli, Silvia Romano

  • 1Department of Neurological Sciences, La Sapienza University, V.le Università 30, 00185 Rome, Italy. carlo.pozzilli@uniromal.it

Journal of the Neurological Sciences
|July 21, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Targeting shared immune pathways in multiple sclerosis and type 1 diabetes: Therapeutic insights from monoclonal antibodies.

Autoimmunity reviews·2026
Same author

Stroke literacy in a sample of Italian adults: an iceberg model revealing domain-specific gaps beyond apparent emergency awareness.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same author

Spinal cord imaging for multiple sclerosis: Advances, priorities, and opportunities.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Use of High-Efficacy Therapy in Children With Multiple Sclerosis to Prevent Long-Term Disability.

Neurology·2026
Same author

Clinical, structural, and functional MRI features predicting PIRMA at 5-year follow-up in multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Distinguishing drug-target effects from natural lipid variation and incorporating imaging outcomes in Mendelian randomisation studies of multiple sclerosis.

Journal of the neurological sciences·2026
Same journal

Long-term social cognitive impairment after ischemic stroke: Frequency and association with lesion volume and location in an exploratory pilot study.

Journal of the neurological sciences·2026
Same journal

Subjective cognitive decline among U.S. Cancer survivors, 2017-2024: Prevalence, cancer-specific patterns, and associated factors.

Journal of the neurological sciences·2026
Same journal

Comment on "Comparative impact of mental and cardiovascular comorbidities on adverse outcomes in people with MS".

Journal of the neurological sciences·2026
Same journal

Comment on "Efficacy and safety of conventional immunosuppressant therapies in elderly patients with Neuromyelitis optica spectrum disorder: A target trial emulation study".

Journal of the neurological sciences·2026
Same journal

Increasing incidence of varicella-zoster virus meningitis in Japan, 2011-2022.

Journal of the neurological sciences·2026
See all related articles

Corticosteroids (Cs) effectively treat multiple sclerosis (MS) relapses by reducing symptom severity and promoting faster recovery. Chronic Cs use also diminishes brain atrophy and lesion formation in MS patients.

Area of Science:

  • Neuroimmunology
  • Pharmacology

Background:

  • Corticosteroids (Cs) are standard treatments for multiple sclerosis (MS) acute relapses.
  • Their efficacy stems from potent immunosuppressive and anti-inflammatory actions.

Purpose of the Study:

  • To evaluate the impact of corticosteroids on multiple sclerosis relapse severity, recovery, and disease progression.
  • To assess the combined effects of methylprednisolone and interferon beta (IFNbeta) in RRMS patients.

Main Methods:

  • Review of clinical data on corticosteroid administration in relapsing-remitting (RR) MS and secondary progressive (SP) MS.
  • Analysis of lesion formation, brain atrophy, and disability progression.
  • Examination of outcomes for combination therapy with methylprednisolone and IFNbeta.

Related Experiment Videos

Main Results:

  • Short-term Cs administration reduces MS relapse severity and speeds recovery.
  • Chronic Cs use decreases T1 hypointense lesions and brain atrophy.
  • Cs treatment delays disability onset in SP MS.
  • Combination therapy with methylprednisolone and IFNbeta enhances lesion recovery and reduces anti-IFNbeta antibody formation in RRMS.

Conclusions:

  • Corticosteroids are crucial for managing MS relapses and slowing disease progression.
  • Combination therapy offers additional benefits in RRMS by improving lesion recovery and mitigating immune responses to IFNbeta.